Zymeworks Cuts C-Suite In Half At Crunch Time For Pipeline
Looking To Be More Cost-Efficient
New Zymeworks CEO Ken Galbraith is laying off at least 25% of the company's staff, including 50% of the senior management team, as the firm looks to advance pivotal trials of its HER2-targeted bispecific antibody zanidatamab.
